MCCC1 (Methylcrotonoyl-CoA Carboxylase 1) encodes the alpha subunit of methylcrotonoyl-CoA carboxylase (MCC), a biotin-dependent mitochondrial enzyme that plays a critical role in the catabolism of the branched-chain amino acid leucine[1]. Located in the mitochondrial matrix, MCC catalyzes the carboxylation of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, an essential step in the leucine degradation pathway that generates acetyl-CoA and acetoacetate for energy production[2].
This gene has garnered significant attention in the context of neurodegenerative diseases due to its dual role in amino acid metabolism and mitochondrial function. MCCC1 mutations cause 3-methylcrotonyl-CoA carboxylase deficiency (MCCD), a rare autosomal recessive metabolic disorder that can present with severe neurological manifestations including developmental delay, seizures, and progressive encephalopathy[3]. Furthermore, emerging research suggests that alterations in MCCC1 expression and activity may contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions through effects on mitochondrial energy metabolism and branched-chain amino acid (BCAA) homeostasis[4][5].
| Property | Value |
|---|---|
| Gene Symbol | MCCC1 |
| Full Name | Methylcrotonoyl-CoA Carboxylase 1 |
| Alternative Names | MCC alpha, MCCA |
| Chromosomal Location | 3q27.1 |
| NCBI Gene ID | 56955 |
| OMIM ID | 210200 |
| Ensembl ID | ENSG00000071889 |
| UniProt ID | Q9P2R3 |
| Protein Length | 726 amino acids |
| Molecular Weight | ~82 kDa |
| Associated Diseases | 3-Methylcrotonyl-CoA Carboxylase Deficiency, Parkinson's Disease, Alzheimer's Disease |
The MCCC1 gene is located on chromosome 3q27.1 and consists of 26 exons spanning approximately 30 kb of genomic DNA. The gene encodes a precursor protein that is imported into mitochondria after synthesis in the cytosol.
MCCC1 is evolutionarily conserved across eukaryotes:
Methylcrotonoyl-CoA carboxylase is a heterododecameric complex consisting of[1:1]:
MCC catalyzes an ATP-dependent carboxylation reaction:
Reaction steps:
MCC requires biotin as an essential cofactor[6]:
MCCC1 is essential for leucine degradation[7]:
Leucine → α-Ketoisocaproate → Isovaleryl-CoA → 3-Methylcrotonyl-CoA
↓ (MCC)
3-Methylglutaconyl-CoA → 3-Hydroxy-3-methylglutaryl-CoA
↓
Acetoacetate + Acetyl-CoA → Ketogenesis / TCA Cycle
MCC contributes to mitochondrial function[8]:
Proper MCCC1 function maintains[9]:
MCCC1 is expressed in various tissues with highest levels in:
| Tissue | Expression Level | Metabolic Context |
|---|---|---|
| Liver | Very high | Primary leucine catabolism |
| Kidney | High | Gluconeogenesis |
| Heart | High | Energy metabolism |
| Skeletal muscle | High | BCAA catabolism |
| Brain | Moderate | Neural metabolism |
| Lung | Moderate | General metabolism |
Within the brain, MCCC1 is expressed in[10]:
MCCC1 expression is regulated by:
MCCC1 dysfunction may contribute to AD pathogenesis through[9:1]:
Targeting MCCC1 in AD:
MCCC1 alterations in PD include[10:1][11]:
Paradoxically, while leucine is essential:
MCCD (OMIM #210200) is an autosomal recessive disorder[2:1]:
| Feature | Typical Presentation |
|---|---|
| Onset | Infancy to early childhood |
| Developmental delay | Variable severity |
| Seizures | Common |
| Cardiomyopathy | Can occur |
| Hypotonia | Profound weakness |
| Metabolic crisis | Triggered by illness/fasting |
MCCC1-based therapeutic strategies[12]:
| Approach | Mechanism | Status |
|---|---|---|
| Ketogenic diet | Bypass metabolic block | Clinical use |
| Ketone esters | Provide alternative fuel | Research |
| Gene therapy | Restore MCCC1 function | Preclinical |
| Biotin supplementation | Cofactor support | Adjunct therapy |
MCCC1 interacts with multiple metabolic enzymes:
| Enzyme | Pathway | Relationship |
|---|---|---|
| BCKDH | Leucine catabolism | Upstream step |
| HMGCS2 | Ketogenesis | Downstream step |
| ACAT1 | Ketone body utilization | Downstream |
| CS | TCA cycle | Provides acetyl-CoA |
| IDH3 | TCA cycle | Provides α-KG |
MCCC1-related metabolites as disease biomarkers:
| Metabolite | Disease | Direction | Utility |
|---|---|---|---|
| 3-Hydroxyisovaleric acid | MCCD | Elevated | Diagnostic |
| Leucine | AD/PD | Altered | Research |
| Ketone bodies | AD/PD | Reduced | Prognostic |
| 3-Methylcrotonylglycine | MCCD | Elevated | Diagnostic |
MCCC1 knockout mice:
| Species | MCCC1 Features | Notes |
|---|---|---|
| Human | Full-length enzyme | 726 aa |
| Mouse | Highly conserved | 725 aa |
| Zebrafish | Functional ortholog | Brain expression |
| Drosophila | Homolog identified | Metabolic function |
| Yeast | MAS1 protein | Mitochondrial |
Alternative splicing generates multiple MCCC1 isoforms:
MCCC1 represents a critical intersection between amino acid metabolism, mitochondrial function, and neurodegenerative disease. While primarily known for its role in leucine catabolism and the rare metabolic disorder MCC deficiency, emerging evidence suggests that alterations in MCCC1 function may contribute to the pathogenesis of more common neurodegenerative conditions including Alzheimer's and Parkinson's diseases. The enzyme's position at the crossroads of branched-chain amino acid metabolism, ketogenesis, and mitochondrial energy production makes it an important therapeutic target. Understanding the precise molecular mechanisms by which MCCC1 dysfunction contributes to neurodegeneration—and developing effective interventions—remains an important area of ongoing research.
Baumgartner MR, et al. Molecular characterization of the human gene encoding methylcrotonoyl-CoA carboxylase. Journal of Biological Chemistry. 2001. ↩︎ ↩︎
Gallagher RC, et al. 3-Methylcrotonyl-CoA carboxylase deficiency: from pathophysiology to treatment. Journal of Inherited Metabolic Disease. 2019. ↩︎ ↩︎
Leonard JV, et al. The metabolic disorders. Journal of Inherited Metabolic Disease. 2000. ↩︎
Mullen SA, et al. Leucine metabolism and neurological disease. Journal of Neurology. 2012. ↩︎
Wang J, et al. Mitochondrial dysfunction in neurodegenerative diseases. Neurobiology of Aging. 2018. ↩︎
Chen D, et al. Biotin-dependent carboxylases in brain metabolism. Journal of Neurochemistry. 2022. ↩︎
Yang L, et al. Leucine catabolism and mitochondrial function. Cellular and Molecular Neurobiology. 2021. ↩︎
Garcia M, et al. Mitochondrial metabolic enzymes in neuroprotection. Free Radical Biology and Medicine. 2021. ↩︎
Huang J, et al. Branched-chain amino acid metabolism in Alzheimer's disease. Journal of Alzheimer's Disease. 2019. ↩︎ ↩︎
Chen X, et al. Methylcrotonyl-CoA carboxylase in Parkinson's disease. Movement Disorders. 2020. ↩︎ ↩︎
Liu Y, et al. BCAT1 and MCCC1 in neurodegeneration: shared pathways. Molecular Neurobiology. 2022. ↩︎
Zhang R, et al. Methylcrotonoyl-CoA carboxylase activity in aging brain. Aging Cell. 2023. ↩︎